<DOC>
	<DOCNO>NCT01316315</DOCNO>
	<brief_summary>The purpose study determine whether single IV dose N6022 significant bronchoprotective effect , compare placebo , methacholine challenge .</brief_summary>
	<brief_title>Study Evaluate Bronchoprotective Effects Single Dose N6022 Patients With Mild Asthma</brief_title>
	<detailed_description>The number patient adverse event measure treated placebo group start dose Day 28 post dose .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Body mass index ( BMI ) 18.5 35 kg/m2 , inclusive , screen . Patient ≤ 5 pack year smoke history nonsmoking ≥ one year . Documented history mild bronchial asthma , first diagnose least 6 month currently treat intermittent shortacting betaagonist therapy inhalation . Prebronchodilator FEV1 ≥ 75 % predict screening . Sensitivity methacholine provocation concentration methacholine result 20 % fall FEV1 ( PC20 methacholine ) ≤ 8 mg/ml screening . Demonstrated stable lung function screen ≤10 % variability two assessment FEV1 take least 7 day apart approximately time day . Hypertension screen define systolic blood pressure ( BP ) &gt; 150 mmHg diastolic BP &gt; 90mmHg . Respiratory tract infection and/or exacerbation asthma within prior 4 week History lifethreatening asthma Administration steroid within 4 week screen visit . History unable tolerate complete MCh testing . Blood donation ( 500 mL ) within 3 month start clinical study . Tested positive hepatitis C antibody hepatitis B surface antigen . Tested positive human immunodeficiency virus ( HIV ) antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>